» Articles » PMID: 29076185

Test-compatible Confidence Intervals for Adaptive Two-stage Single-arm Designs with Binary Endpoint

Overview
Journal Biom J
Specialty Public Health
Date 2017 Oct 28
PMID 29076185
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Inference after two-stage single-arm designs with binary endpoint is challenging due to the nonunique ordering of the sampling space in multistage designs. We illustrate the problem of specifying test-compatible confidence intervals for designs with nonconstant second-stage sample size and present two approaches that guarantee confidence intervals consistent with the test decision. Firstly, we extend the well-known Clopper-Pearson approach of inverting a family of two-sided hypothesis tests from the group-sequential case to designs with fully adaptive sample size. Test compatibility is achieved by using a sample space ordering that is derived from a test-compatible estimator. The resulting confidence intervals tend to be conservative but assure the nominal coverage probability. In order to assess the possibility of further improving these confidence intervals, we pursue a direct optimization approach minimizing the mean width of the confidence intervals. While the latter approach produces more stable coverage probabilities, it is also slightly anti-conservative and yields only negligible improvements in mean width. We conclude that the Clopper-Pearson-type confidence intervals based on a test-compatible estimator are the best choice if the nominal coverage probability is not to be undershot and compatibility of test decision and confidence interval is to be preserved.

Citing Articles

Point estimation for adaptive trial designs I: A methodological review.

Robertson D, Choodari-Oskooei B, Dimairo M, Flight L, Pallmann P, Jaki T Stat Med. 2022; 42(2):122-145.

PMID: 36451173 PMC: 7613995. DOI: 10.1002/sim.9605.


Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem-ion): study protocol for a randomized phase II pilot trial.

Brugemann D, Lehner B, Kieser M, Krisam J, Hommertgen A, Jaekel C BMC Cancer. 2022; 22(1):538.

PMID: 35550036 PMC: 9097299. DOI: 10.1186/s12885-022-09560-x.


Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.

Bozorgmehr F, Chung I, Christopoulos P, Krisam J, Schneider M, Bruckner L BMC Cancer. 2020; 20(1):806.

PMID: 32842974 PMC: 7447611. DOI: 10.1186/s12885-020-07264-8.


Re-formulating Gehan's design as a flexible two-stage single-arm trial.

Grayling M, Mander A BMC Med Res Methodol. 2019; 19(1):22.

PMID: 30691398 PMC: 6350340. DOI: 10.1186/s12874-019-0659-2.